Research & Development
The Enzymatica Research Journey
Enzymatica is a leader in enzyme science.
From discovery to development, Enzymatica has been asking ‘how can trypsin enzymes affect greater patient care?’ This pursuit and long-term commitment has led to a healthcare innovation that will change the way we think about and approach upper respiratory health.
This has led to a technology platform with a post-pandemic global significance due to its ability to help the human body protect itself from airborne viruses such as those that cause the common cold.
Enzymatica’s research has pursued a path to validate trypsin’s full potential to bring proven health-protection people can easily use and trust in their daily lives.
Enzymatica describes this as `The Science That Protects`.
Backed by years of research, Enzymatica’s unique enzyme science has been developed throughout a testing programme spanning 3 stages and involving both laboratory-based and real-world usage evidence.
Stage 1Enzyme Exploration: In-Vitro
Evaluating barrier protection and its measured effectiveness in high need, vulnerable population groups, including effectiveness against the main cold-causing viruses.
A medical device forming a protective barrier that deactivates four major common cold viruses
Nov. 2017
Bjarki Stefanson, Augusta Gudmundsdottir, A. Clarsund
Stage 2Proof of Concept - Common Cold: In-Vivo
Assessingʼ viral load reduction scope and ability to protect people from the causes of the common cold, including its influence over symptoms and impact on human quality of life.
Evaluation of ColdZyme Mouthspray against common cold in elderly care personnel
Feb. 2017
Mats Clarsund, Christina Bråkenhielm Persson
A Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Study on ColdZyme® Mouth Spray against Rhinovirus-Induced Common Cold
Nov. 2017
Mats Clarsund1*, Marcus Fornbacke1, Lena Uller2, Sebastian L. Johnston3, Cecilia Ahlström Emanuelsson4
1Enzymatica AB, Lund, Sweden
2Unit of Respiratory Immunopharmacology, Department of Experimental Medical Science, Lund University, Lund, Sweden
3Airway Disease Infection Section, National Heart and Lung Institute, Imperial College, London, UK
4Department of Otorhinolaryngology, Skåne University Hospital, Lund, Sweden
Evaluation of ColdZyme Mouth Spray against Common Cold in Preschool Staff
Nov. 2017
Mats Clarsund
Enzymatica AB, Lund, Sweden
Multi-symptom Relief and Improvement of Quality of Life - A Comparative Multicenter Trial on ColdZyme® Mouth Spray in Common Cold
Apr. 2019
Fredrik Lindberg, Enzymatica AB, Lund, Sweden
Coldzyme® Mouth Spray reduces duration of upper respiratory tract infection symptoms in endurance athletes under free living conditions - Randomised to control study for a 3-months period
Jun. 2020
Glen Davison, University of Kent, Canterbury, UK
Stage 3Proof of Concept: Broader Upper Respiratory Tract Infections
Measuring protective effectiveness against a broadened range of upper respiratory viruses, testing over 10 major airborne virus types and subvariants using real-world evidence.
Inactivation of SARS CoV-2 and HCoV-229E in vitro by ColdZyme®
Oct. 2022
Gudmundsdottir Á, Scheving R, Lindberg F, Stefansson B
ColdZyme® protects airway epithelia from infection with BA.4/5 | Respiratory Research | Full Text (biomedcentral.com)
Oct. 2022
Viktoria Zaderer, Stefanie Dichtl, Rosa Bellmann Weiler, Cornelia Lass Flörl, Wilfried Posch & Doris Wilflingseder
ColdZyme breaks viral infection cycle – significantly reducing influenza viral load
Aug. 2023
Doris Wilflingseder, Medical University of Innsbruck, Austria
Effects of ColdZyme® Mouth Spray on upper respiratory tract infection URTI duration and viral load in endurance athletes.
Sep. 2023
Glen Davison, University of Kent, Canterbury, UK